Novo Nordisk’s Experimental Diabetes Treatment Achieves Better Blood Sugar Targets Than Insulin Degludec
September 22, 11:23 AM
Novo Nordisk A/S (NYSE:NVO) presented new data from the phase 3a ONWARDS 2 trial of insulin icodec in type 2 diabetes…
September 7, 7:00 AM
Zealand Pharma A/S (NASDAQ:ZEAL) has entered into a global license and development agreement with Novo Nordisk A/S (NYSE:NVO) to commercialize Zegalogue (dasiglucagon) for…
Zealand Pharma Announced Global License and Development Agreement with Novo Nordisk for ZEGALOGUE; Zealand to Receive Upfront Payment of DKK 25M Plus Up to DKK 45M in Milestones
September 7, 4:53 AM
Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced it has entered into a global license and development agreement with Novo Nordisk A/S to commercialize ZEGALOGUE® (dasiglucagon) for injection.
August 31, 11:38 AM
- Dow Jones Justice Dept.
August 29, 8:06 AM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced
August 19, 2:01 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
August 5, 4:00 AM
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.
Novo Nordisk Late Wednesday Reported Q2 EPS $0.84 Beats $0.82 Estimate, Sales $5.91B Beat $5.81B Estimate
August 4, 3:18 PM
Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.82 by 2.44 percent. This is a 1.18 percent decrease over earnings of $0.85 per share from the same